Mind-body Treatments for Chronic Back Pain

Not Applicable

Completed

Conditions: Back Pain Lower Back Chronic
Back Pain, Low
Chronic Pain

Interventions: Other: Open-Label Placebo Treatment for Chronic Back Pain
Behavioral: Psychotherapy Treatment for Chronic Back Pain

Registration Number: NCT03294148

Lead Sponsor: University of Colorado, Boulder

Brief Summary: Participants with chronic back pain will complete an online prescreen. They will then be randomized to one of two different studies: a placebo vs. waitlist study or a psychotherapy vs. waitlist study, with randomization stratified on pain intensity, age, gender, and opioid use. Participants will then complete an in-person eligibility session, and eligible participants will be scheduled for the baseline assessment session. Following the baseline assessment session, participants will then be randomized to the treatment group or the waitlist group (with a ratio of 2:1 treatment:waitlist), using a computer-generated random sequence.

This scheme will result in three equally sized groups-placebo, psychotherapy, and waitlist-as the investigators will collapse data from the waitlist arms in the two studies for analyses. The investigators do not use a standard three-way randomization because the investigators do not want placebo participants to think they are in a control condition. Thus, the investigators constrain participant's expectations to either injection vs. waitlist or to psychotherapy vs. waitlist.

The placebo treatment is a subcutaneous injection of saline into the back. Participants will know that the treatment is a placebo, i.e., it is an "open label" placebo. Psychotherapy (8 sessions) will be supervised by Alan Gordon and Howard Schubiner.

Functional MRI brain imaging, self-reported clinical outcomes, and behavioral measures will be collected pre- and post-treatment. A brief follow-up survey will be sent at months 1, 2, 3, 6, and 12 after the final assessment session. These will provide longer term data about the trajectory and durability of patient improvement.

Additionally, a group of healthy controls, with no history of back pain, will complete the baseline assessment. They will serve as a comparison group to probe whether the patterns of observed brain activity is specific to CBP patients.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 151

Inclusion Criteria

Participants aged 21 to 70 with CBP will be enrolled.
CBP will be defined according to the criteria established by a recent NIH task force (Deyo et al., 2014). Pain duration must be at least 3 months, with back pain being an ongoing problem for at least half the days of the last 6 months. That is, patients can meet criteria by either reporting pain every day for the past 3 months, or by reporting pain on half or more of the days for the past 6+ months. This will be determined by asking patients: (1) How long has back pain has been an ongoing problem for you? (2) How often has low back pain been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1 and a response of ''at least half the days in the past 6 months'' to question 2 would define CBP.
Patients must rate pain intensity at 40/100 or greater on the Brief Pain Inventory-Short Form (BPI-SF), in keeping with inclusion criteria from previous CBP trials (Baliki et al., 2012; Cherkin et al., 2016; Hashmi et al., 2013; Seminowicz et al., 2011).
Back pain must be elicited by our back pain device (see below).
Participants must also be comfortable and able to communicate via email or text message, as several study measures are collected in this manner (see below).

Exclusion Criteria

Back pain associated with compensation or litigation issues as determined by self-report within the past year.
Leg pain is greater than back pain. This suggests neuropathic pain, which may be less responsive to placebo or psychotherapy.
Difficulty participating for technical/logistical issues (e.g., unable to get to assessment sessions).
Self-reported diagnoses of schizophrenia, multiple personality disorder, or dissociative identity disorder.
Self-reported use of intravenous drugs, due to concerns about infections and subject compliance with experimental protocols.
Inability to undergo MRI as determined by MRI safety screen (e.g., pregnancy, metal in body, claustrophobia, using the standard screen conducted by the MRI imaging facility).
Hypersensitive or hyposensitive to pressure pain: unable to tolerate 7kg/cm2 stimulation or reporting no pain for 4kg/cm2 stimulation; see further details below.
Current regular use of an immunosuppressant drug, such as steroids. Such drugs interfere with immunoassay results.
Self-reported history of metastasizing cancers-cancer of the breast, thyroid, lung, kidney, prostate or blood cancers.
Self-reported history of stroke, brain surgery, or brain tumor.
Self-reported diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus, or polymyositis.
Unexplained, unintended weight loss of 20 lbs. or more in the past year.
Cauda Equina syndrome, as screened for by self-reported inability to control bowel or bladder function.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Open-Label Placebo Treatment for Chronic Back Pain	The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (\~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
Psychotherapy	Psychotherapy Treatment for Chronic Back Pain	Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.

Primary Outcome Measures

Name	Time	Method
Brief Pain Inventory-Short Form (BPI-SF)	At post-treatment fMRI session, approximately 1 month after randomization	1-week average pain intensity, 0 - 10 numerical rating scale, where a higher score indicates more pain.

Secondary Outcome Measures

Name	Time	Method
Timeline Follow-Back Measure for Alcohol (TLFB)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire used to assess daily drinking (number of drinks consumed over past two weeks)
Treatment Satisfaction Questionnaire	At post-treatment fMRI session, approximately 1 month after randomization	Post-treatment-only outcome measure depicting the patient's satisfaction with the treatment. Measured 0 - 100. A higher score means higher satisfaction with treatment/
Timeline Follow-Back Measure for Cannabis (TLFB)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire used to assess daily cannabis use (number of grams consumed over past two weeks)
Positive Affect Scale Short Form (PANAS-SF)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire to rate positive affect, scores range from 5 - 25, a higher score means stronger affect
Tampa Scale of Kinesiophobia (TSK)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire used to assess the subjective rating of kinesiophobia or fear of movement. Scores range from 11-44 with higher scores indicating greater fear of pain, movement, and injury.
Pain Catastrophizing Questionnaire (PCS)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire used to help quantify an individual's pain experience. Measured 0-52. A higher score means a higher level of catastrophizing.
PROMIS- Depression	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire measuring depression (8 items). Scores range from 8-32. A higher score indicates higher levels of depressive symptoms
Patient Global Impression of Change (PGIC)	At post-treatment fMRI session, approximately 1 month after randomization	Post-treatment-only outcome measure depicting a patient's subjective rating of overall improvement. Score ranges from 1-7 with a higher score indicating a higher level of change and improvement
Negative Affect Scale Short Form (PANAS-SF)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire to rate negative affect, scores range from 5 - 25, with a higher score meaning a stronger negative affect
Oswestry Disability Index	At post-treatment fMRI session, approximately 1 month after randomization	Back pain disability questionnaire measured on a scale of 0-100. A higher score indicates a higher severity of disability.
PROMIS Anger	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire measuring anger (5 items) with a score range of 5-25. Higher scores indicate a higher severity of anger.
PROMIS Sleep	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire measuring sleep disturbance (8 items). Scores range from 8-40. Higher scores indicate higher levels of sleep disturbance
PROMIS Anxiety	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire measuring anxiety (8 items). Scores range from 8-40 with a higher score meaning more severe levels of fear, anxious misery, hyperarousal, and somatic symptoms related to arousal.
Timeline Follow-Back Measure for Opioid Use (TLFB)	At post-treatment fMRI session, approximately 1 month after randomization	Questionnaire used to assess daily opioid use (number of pills consumed over past two weeks)